



## ASX ANNOUNCEMENT

### Lumos Diagnostics Expands Henry Schein Distribution Partnership for FebriDx®

#### Rapid point-of-care test available to health care practitioners in Belgium

**MELBOURNE, Australia (9 July 2024)** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, has extended its agreement with Henry Schein Medical’s European business for the FebriDx® point-of-care test. The agreement further expands the distribution of FebriDx® through Henry Schein’s Medical business to include Belgium.

FebriDx® is a rapid POC test to differentiate a viral from bacterial acute respiratory infection. FebriDx® delivers results after 10 minutes from a fingerstick blood sample and can be used to help rapidly and accurately manage infectious patients in Primary Care, Urgent Care, Emergency Dept, Paediatric and other Outpatient settings.

Henry Schein, Inc (Nasdaq: HSIC) is the world’s largest provider of health care solutions to office-based dental and medical practitioners, currently distributes the FebriDx® test in the Netherlands, Portugal, Spain, the UK, and the US. Henry Schein’s Medical business expanded into the Belgium market in 2023, specifically serving general practitioners and midwives.

“Our team is dedicated to providing innovative, integrated health care products, together with our supplier partners, that customers can rely on,” said Alain Nijsing, General Manager of Henry Schein Medical Netherlands and Belgium. “By partnering with Lumos to now offer FebriDx® in Belgium, we can help health care professionals around the world have access to the tools needed to continue providing quality care.”

According to the Belgian Federal Public Service (FPS) Health, Food Chain, Safety and Environment<sup>1</sup>, antimicrobial resistance is one of the greatest threats to public health today and in the future. Recently, an independent study by UK researchers, published in the Journal of Antimicrobial Chemotherapy<sup>2</sup>, has

---

<sup>1</sup> Belgian Federal Public Service (FPS) Health, Food Chain, Safety and Environment. <https://www.health.belgium.be/en/combating-antimicrobial-resistance-amr#PlandactionOneHealth>.

<sup>2</sup> Journal of Antimicrobial Chemotherapy. <https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaf127/7665279?login=false>.

shown that using FebriDx® led to a reduction in antibiotic prescribing intentions for patients with lower respiratory tract infections. In primary care, lower respiratory tract infections are a common reason for antibiotic prescriptions.

“We are pleased to continue to partner with Henry Schein in various countries to provide access to FebriDx® and help address the global challenge of antimicrobial resistance,” said Doug Ward, CEO of Lumos Diagnostics. “By providing clinicians with rapid and accurate information about the nature of a patient's infection, FebriDx® can help health care professionals make more informed decisions about antibiotic use, ultimately benefiting both individual patients and public health.”

-Ends-

*This announcement has been approved by the Lumos Disclosure Committee.*

#### **About Lumos Diagnostics**

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](https://lumosdiagnostics.com).

#### **About Henry Schein, Inc.**

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 [Team Schein Members](#) worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based [dental](#) and [medical](#) practitioners work more efficiently so they can provide quality care more effectively. These solutions also support [dental laboratories](#), [government and institutional health care clinics](#), as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached \$12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

For personal use only

For more information, visit Henry Schein at the company's corporate website [www.henryschein.com](http://www.henryschein.com) or at [www.henryschein.be](http://www.henryschein.be) for Henry Schein Medical in Belgium.

### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

#### **Media Contact:**

Haley Chartres – Australia  
H^CK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 (0) 423 139 163

#### Henry Schein Media Contact:

Lauren DelGuidice  
Sr. Corporate Media Relations Specialist  
[Lauren.delguidice@henryschein.com](mailto:Lauren.delguidice@henryschein.com)  
1-631-479-7309

#### **Investor Contact:**

Jane Lowe  
Managing Director, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 411 117 774

#### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205, Australia  
+61 3 9087 1598

For personal use only